$GRAL

Grail's Galleri cancer-detection test, priced at $949, is not covered by Medicare. FDA advisory panel supported its effectiveness, safety, and risk-benefit profile. Medicare coverage may start in 2029, but age restrictions could exclude some beneficiaries. Grail expects FDA decision by early Q1 2027. Promotional pricing and other coverage options may reduce out-of-pocket costs.

Grail Inc (GRAL) reported Q3 revenue of $37.5M, missing estimates by 17%. The company posted a loss of $2.21 per share, with revenue up 4% YoY. Galleri test revenue grew 14% YoY to $37.3M. Stock fell 11.5% in after-hours trading. FDA Advisory Committee voted in favor of Galleri test approval. GRAL anticipates an FDA decision by early Q1 2027. Q3 net loss was $103.6M, up from $89.0M YoY.

Grail (GRAL) reported Q3 sales of $37.5M, missing estimates of $44.2M. The company, a spinoff of Illumina (ILMN), lost $2.21 per share. Its stock has nearly doubled since mid-September but fell after the earnings report.

GRAIL, Inc. (GRAL) shares rose after an FDA panel backed its cancer detection test, potentially leading to FDA approval and insurance coverage. The company's stock has traded between $41.50 and $166.48 over the past year, closing at $133.76 on November 2, 2026. Mott Capital Management highlighted GRAL in its Q3 2026 investor letter, noting the test's potential and the role of AI in its development.

GRAIL (GRAL) burned $81.2M in cash in Q2 2026, with cash burn rate at 181.6% of sales, down from 217.6% YoY. Cash reserves of $862M could last ~12 quarters at current burn rate. Management expects FDA approval in early 2027, but a panel was divided on effectiveness.

GRAIL, Inc. (GRAL) will release its Q3 2026 financial results on Nov. 4, 2026, followed by a webcast and conference call to discuss results and business progress. The company focuses on early cancer detection using advanced technologies. Details and registration for the call are available on GRAIL's investor relations website.

Ofman Joshua J. (Chief Executive Officer) sold 20,000 shares of GRAIL, Inc. (GRAL) at an average of $136.85 ($133.12–$138.79, $2.74M total) across 6 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

TD Cowen raised its price target for Grail (NASDAQ:GRAL) to $180 from $88, citing increased FDA approval prospects and CMS reimbursement confidence. The stock has surged 186% in six months. Analysts highlight high valuation multiples and regulatory developments as key factors. Grail develops early cancer detection tests.

Grail (GRAL) stock rose 80% in a month after FDA panel backed its Galleri test, but insurers' pricing decisions remain a key risk factor. The test's adoption depends on cost-benefit analysis, including false positives and pricing at $949.

GRAIL (GRAL) and Guardant Health (GH) both sell cancer-detection blood tests. GH has higher revenue ($1.18B vs $165M), growth (44.30% vs 25.70%), and market cap ($22.59B vs $5.94B), but GRAL has more cash ($861.61M vs $1.05B) and less debt ($91.31M vs $1.70B). Both lack earnings, with GRAL at $133 and GH at $168 as of October 7.